武田制药(TAK)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TAK 武田制药

交易中 05-13 14:55:46 EDT

13.14

-0.11

-0.87%

最高13.21	最低13.11	成交量123.10万
今开13.17	昨收13.25	日振幅0.75%
总市值412.16亿	流通市值407.18亿	总股本31.38亿
成交额1,618万	换手率0.04%	流通股本31.00亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"TAK","market":"US","secType":"STK","nameCN":"武田制药","latestPrice":13.135,"timestamp":1715626533419,"preClose":13.25,"halted":0,"volume":1231002,"delay":0,"floatShares":3099967594,"shares":3137867702,"eps":0.301345,"marketStatus":"交易中","marketStatusCode":2,"change":-0.115,"latestTime":"05-13 14:55:46 EDT","open":13.17,"high":13.21,"low":13.11,"amount":16181158.14441,"amplitude":0.007547,"askPrice":13.14,"askSize":1466,"bidPrice":13.13,"bidSize":3293,"shortable":3,"etf":0,"ttmEps":0.301345,"exchange":"NYSE","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1715630400000},"adr":0,"listingDate":1545627600000,"adjPreClose":13.25,"adrRate":0.5,"dividendRate":0.045916,"preHourTrading":{"tag":"盘前","latestPrice":13.17,"preClose":13.25,"latestTime":"09:17 EDT","volume":6766,"amount":88656.102348,"timestamp":1715606220524},"postHourTrading":{"tag":"盘后","latestPrice":13.2,"preClose":13.25,"latestTime":"19:19 EDT","volume":519,"amount":6851.5828,"timestamp":1715383163283},"volumeRatio":0.754292},"requestUrl":"/m/hq/s/TAK","defaultTab":"news","newsList":[{"id":"2435320698","title":"武田制药(TAK.US)引进AC Immune阿尔茨海默症Aβ疫苗疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2435320698","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2435320698?lang=zh_cn&edition=full","pubTime":"2024-05-13 21:07","pubTimestamp":1715605667,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，5月13日，武田制药(TAK.US)宣布引进AC Immune的阿尔茨海默症Aβ疫苗疗法ACI-24.060，武田支付1亿美元预付款，约21亿美元里程碑金额，以及中至高十位数的销售分成。据悉，ACI-24.060为一款Aβ疫苗，诱导产生Aβ抗体，以及Th细胞响应，目前处于二期临床阶段。目前阿尔茨海默症获批的新疗法主要是Aβ抗体，而AC Immune的技术路线是Aβ疫苗，注射后可以诱导抗体免疫和细胞免疫。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1120764.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434016556","title":"武田制药2023财年净利润同比下降超54% 宣布重组计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2434016556","media":"新浪财经","top":-1,"share":"https://www.laohu8.com/m/news/2434016556?lang=zh_cn&edition=full","pubTime":"2024-05-09 22:12","pubTimestamp":1715263972,"startTime":"0","endTime":"0","summary":"格隆汇5月9日｜日本武田制药公布2023财年全年业绩，营收为42638亿日元，同比增长5.9%；净利润为1441亿日元，同比下降54.6%；非公认会计准则每股收益为484日元，同比下降13.4%。该公司表示，将在2024财年承担1400亿日元的一次性重组成本。该公司宣布将启动一项多年期计划，根据该计划，武田将优化员工队伍，并投资于技术和数据，以将核心营业利润率提高30%以上。此举将使武田能够“为患者创造更多的长期价值”。股市回暖，抄底炒股先开户！","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2024-05-09/doc-inaurxyf2717961.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2434065781","title":"武田制药(TAK.US)2023财年净利润同比降低54.6% 将进行1400亿日元重组以提高利润","url":"https://stock-news.laohu8.com/highlight/detail?id=2434065781","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2434065781?lang=zh_cn&edition=full","pubTime":"2024-05-09 16:53","pubTimestamp":1715244780,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，武田制药(TAK.US)公布了2023财年全年业绩，财报显示，武田制药全财年营收为42638亿日元，同比增长5.9%；净利润为1441亿日元，同比降低54.6%；非公认会计准则每股收益为 484 日元，同比降低13.4%。该公司表示，将在2024财年承担1400亿日元(合9亿美元)的一次性重组成本，该公司将启动一项多年期计划，以提高利润率。武田在周四的一份声明中表示，根据该计划，武田将优化员工队伍，并投资于技术和数据，以将核心营业利润率提高30%以上。声明称，此举将使武田能够“为患者创造更多的长期价值”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1119264.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434105193","title":"Takeda Pharmaceutical(TAK.US)：2023年Q4财报实现营收70.82亿美元，前值为72.29亿美元；每股收益为0.24美元，前值为0.39美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2434105193","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2434105193?lang=zh_cn&edition=full","pubTime":"2024-05-09 14:55","pubTimestamp":1715237747,"startTime":"0","endTime":"0","summary":"Takeda Pharmaceutical(TAK.US)：2023年Q4财报实现营收70.82亿美元，前值为72.29亿美元；每股收益为0.24美元，前值为0.39美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050914554987e373a7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050914554987e373a7&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422543608","title":"武田制药总裁：创新为中国医疗健康行业赋予新质生产力","url":"https://stock-news.laohu8.com/highlight/detail?id=2422543608","media":"市场资讯","top":-1,"share":"https://www.laohu8.com/m/news/2422543608?lang=zh_cn&edition=full","pubTime":"2024-03-25 21:48","pubTimestamp":1711374491,"startTime":"0","endTime":"0","summary":"专题：中国发展高层论坛2024年年会来源：CGTN【#先声夺人# |武田制药总裁：创新为中国医疗健康行业赋予新质生产力】3月24日，在中国发展高层论坛2024年年会现场，武田制药总裁卫博科接受CGTN主持人@田薇_TianWei专访。他表示，以大数据疾病诊疗为代表的先进科技的进步将进一步赋能医疗健康领域。在医药领域，实现制药技术与产品的进出口流动较为困难，武田制药将力促进中国制药进一步走向全球。新浪声明：所有会议实录均为现场速记整理，未经演讲者审阅，新浪网登载此文出于传递更多信息之目的，并不意味着赞同其观点或证实其描述。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403252148188b6144da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403252148188b6144da&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2419279615","title":"丰田汽车(TM.US)超越武田制药(TAK.US) 成亚太区最大做空股","url":"https://stock-news.laohu8.com/highlight/detail?id=2419279615","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2419279615?lang=zh_cn&edition=full","pubTime":"2024-03-13 14:46","pubTimestamp":1710312411,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，根据财资管理及证券融资平台Hazeltree周二发布的报告显示，汽车制造商丰田汽车超过武田制药，在二月份成为亚太地区对冲基金做空最多的大型股票。做空交易是押注一家公司的股价下跌。此外，该报告还指出，美国电动汽车制造商特斯拉仍是美洲被做空最多的股票，而奢侈品集团LVMH 连续第六个月成为欧洲、中东和非洲地区的首位。在中型股票方面，列车制造商阿尔斯通和芯片制造商Wolfspeed分别继续是EMEA和美洲地区最受做空的股票。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1085834.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2415259968","title":"百度健康上线罕见病中心，法布雷病及HAE患者可开展线上自筛","url":"https://stock-news.laohu8.com/highlight/detail?id=2415259968","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2415259968?lang=zh_cn&edition=full","pubTime":"2024-02-29 16:11","pubTimestamp":1709194260,"startTime":"0","endTime":"0","summary":"由健康管理平台百度健康携手中国罕见病联盟共建的\"罕见病中心\"正式升级上线。在我国，法布雷病的总体筛查诊断率仅为3%。延迟诊断会增加HAE患者因喉部水肿发作导致的死亡风险。此次百度健康上线\"罕见病中心\"将为这些疾病提供科普和自筛指引，一方面提升大众对于法布雷病及HAE的疾病认知，另一方面帮助公众在面对疾病威胁时能够做到\"早筛查、早发现，早治疗\"，从而提高诊断意识。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4349121_ZH49121_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2409834794","title":"全新机制抗病毒药物马立巴韦片开出全国首处方","url":"https://stock-news.laohu8.com/highlight/detail?id=2409834794","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2409834794?lang=zh_cn&edition=full","pubTime":"2024-02-08 18:44","pubTimestamp":1707389040,"startTime":"0","endTime":"0","summary":"马立巴韦的出现，让我们临床医生有了新的武器来应对移植后的CMV反复感染。期待患者在接受马立巴韦后，能够有良好的预后。作为创新靶向药物，马立巴韦可高效清除CMV血症并控制相关症状，且治疗限制性毒性更低。同时，马立巴韦片与常规抗病毒治疗相比，治疗限制性毒性更低。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4332493_ZH32493_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2403831517","title":"新版国家医保目录落地执行 多发性骨髓瘤IRd治疗方案实现联合报销","url":"https://stock-news.laohu8.com/highlight/detail?id=2403831517","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2403831517?lang=zh_cn&edition=full","pubTime":"2024-01-16 16:14","pubTimestamp":1705392840,"startTime":"0","endTime":"0","summary":"多项国内外临床指南提出，治疗方案的选择是实现多发性骨髓瘤持续治疗的关键。新版医保目录实行后，这些限制都将被取消，这意味着患者使用IRd方案的年自付费用可降低过半。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4312634_ZH12634_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2393207881","title":"武田全新机制抗病毒药物马立巴韦片中国正式获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2393207881","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2393207881?lang=zh_cn&edition=full","pubTime":"2023-12-21 15:07","pubTimestamp":1703142420,"startTime":"0","endTime":"0","summary":"2021年1月，马立巴韦片被国家药品监督管理局药品审评中心正式认定为\"突破性治疗药物品种\"。武田制药全球高级副总裁、武田中国总裁单国洪先生表示：\"感谢政府相关部门近年来鼓励创新药物的一系列利好政策，使马立巴韦片能够通过优先审评审批在中国快速获批。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4299270_ZH99270_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2385545600","title":"武田富马酸伏诺拉生片根除幽门螺杆菌新适应症在中国获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2385545600","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2385545600?lang=zh_cn&edition=full","pubTime":"2023-11-24 13:04","pubTimestamp":1700802240,"startTime":"0","endTime":"0","summary":"以富马酸伏诺拉生片为基础的四联方案是国内目前首个获批的含铋四联方案，将为中国庞大的幽门螺杆菌感染人群提供\"新武器\"，开启\"除幽\"新篇章，夯实胃癌一级预防防线，进一步对我国胃癌防控态势带来积极影响。此次富马酸伏诺拉生片根除幽门螺杆菌新适应症获批主要基于一项在中国人群多中心Ⅲ期研究[10]。迄今为止，富马酸伏诺拉生片与抗生素联用根除幽门螺杆菌的新适应症已在日本、美国等全球15个国家及地区获批。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4276858_ZH76858_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.takeda.com","stockEarnings":[{"period":"1week","weight":-0.009},{"period":"1month","weight":-0.0236},{"period":"3month","weight":-0.0695},{"period":"6month","weight":-0.0321},{"period":"1year","weight":-0.1801},{"period":"ytd","weight":-0.0715}],"compareEarnings":[{"period":"1week","weight":0.0187},{"period":"1month","weight":0.0131},{"period":"3month","weight":0.0392},{"period":"6month","weight":0.1821},{"period":"1year","weight":0.2638},{"period":"ytd","weight":0.0958}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Takeda Pharmaceutical Company Limited是一家在日本注册成立的上市公司成立于1925年1月12日。该公司及其子公司是一家主要的全球制药集团，从事医药产品、非处方药和准药品消费品以及其他医疗保健产品的研究、开发、制造和营销。武田的主要医药产品包括以下治疗领域的药物：胃肠病学、肿瘤学和神经科学。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.03791},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.021005},{"month":3,"riseRate":0.5,"avgChangeRate":-0.007765},{"month":4,"riseRate":0.5,"avgChangeRate":-0.007082},{"month":5,"riseRate":0.5,"avgChangeRate":-0.000418},{"month":6,"riseRate":0.2,"avgChangeRate":-0.017319},{"month":7,"riseRate":0.4,"avgChangeRate":0.000351},{"month":8,"riseRate":0.6,"avgChangeRate":-0.012751},{"month":9,"riseRate":0.4,"avgChangeRate":-0.01721},{"month":10,"riseRate":0.4,"avgChangeRate":-0.067649},{"month":11,"riseRate":0.8,"avgChangeRate":0.079016},{"month":12,"riseRate":0.8,"avgChangeRate":0.016238}],"exchange":"NYSE","name":"武田制药","nameEN":"Takeda Pharmaceutical Co Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"武田制药(TAK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供武田制药(TAK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"武田制药,TAK,武田制药股票,武田制药股票老虎,武田制药股票老虎国际,武田制药行情,武田制药股票行情,武田制药股价,武田制药股市,武田制药股票价格,武田制药股票交易,武田制药股票购买,武田制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"武田制药(TAK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供武田制药(TAK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}